▶Bosentanis predicted to decrease the exposure toribociclib.
oStudy
▶Rifampicinaffects the exposure tobosentan. Avoid.r
Study
▶Bosentanis predicted to decrease the exposure torilpivirine.
Avoid.rTheoretical
▶Bosentanis predicted to decrease the exposure torolapitant.
Avoid.rStudy
▶Bosentanis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oTheoretical
▶Bosentanis predicted to decrease the exposure tosimeprevir.
Avoid.rStudy
▶Bosentanis predicted to decrease the concentration of
sirolimusandsirolimuspotentially increases the
concentration ofbosentan. Avoid.rTheoretical
▶St John’s Wortis predicted to decrease the exposure to
bosentan. Avoid.oTheoretical
▶Bosentanslightly decreases the exposure tostatins
(atorvastatin).nStudy
▶Bosentanmoderately decreases the exposure tostatins
(simvastatin).oStudy
▶Bosentanincreases the risk of hepatotoxicity when given with
sulfonylureas(glibenclamide). Avoid.rStudy
▶Bosentanis predicted to decrease the concentration of
tacrolimusandtacrolimuspotentially increases the
concentration ofbosentan. Avoid.rTheoretical
▶Bosentanis predicted to decrease the exposure totaxanes
(cabazitaxel). Avoid.rStudy
▶Bosentanis predicted to decrease the concentration of
temsirolimus. Avoid.rTheoretical
▶Bosentanis predicted to decrease the exposure toticagrelor.
oTheoretical
▶Bosentanis predicted to decrease the exposure totofacitinib.
oStudy
▶Bosentanis predicted to decrease the exposure totolvaptan.
oTheoretical
▶Bosentandecreases the efficacy ofulipristal. For FSRH
guidance, seeContraceptives, interactionsp. 497.r
Anecdotal
▶Bosentanis predicted to decrease the exposure tovelpatasvir.
Avoid.oTheoretical
▶Bosentanis predicted to decrease the exposure tovenetoclax.
Avoid.rStudy
▶Bosentanis predicted to decrease the concentration of
voxilaprevir. Avoid.rTheoretical
Bosutinib→seeTABLE 15p. 850 (myelosuppression),TABLE 9p. 849
(QT-interval prolongation)
▶Antacidsare predicted to decrease the absorption ofbosutinib.
Bosutinibshould be taken at least 12 hours beforeantacids.
oTheoretical
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tobosutinib. Avoid or adjust dose.r
Theoretical→Also seeTABLE 9p. 849
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to very markedly decrease
the exposure tobosutinib. Avoid.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tobosutinib. Avoid or
adjust dose.rTheoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to markedly increase the exposure tobosutinib.
Avoid or adjust dose.rStudy→Also seeTABLE 9p. 849
▶Aprepitantis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical
▶Bosentanis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobosutinib. Avoid or adjust dose.
rTheoretical
▶Cobicistatis predicted to markedly increase the exposure to
bosutinib. Avoid or adjust dose.rStudy
▶Bosutinibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Crizotinibis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15
p. 850→Also seeTABLE 9p. 849
▶Efavirenzis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical→Also seeTABLE 9p. 849
▶Enzalutamideis predicted to very markedly decrease the
exposure tobosutinib. Avoid.rStudy
▶Etravirineis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Fosaprepitantis predicted to increase the exposure to
bosutinib.rTheoretical
▶Grapefruit juiceis predicted to increase the exposure to
bosutinib. Avoid.oTheoretical
▶H 2 receptor antagonistsare predicted to decrease the
absorption ofbosutinib.oTheoretical
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure tobosutinib. Avoid or adjust dose.rStudy→
Also seeTABLE 9p. 849
▶Idelalisibis predicted to markedly increase the exposure to
bosutinib. Avoid or adjust dose.rStudy→Also seeTABLE 15
p. 850
▶Imatinibis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15p. 850
▶Macrolides(clarithromycin)are predicted to markedly increase
the exposure tobosutinib. Avoid or adjust dose.rStudy→
Also seeTABLE 9p. 849
▶Macrolides(erythromycin)are predicted to increase the
exposure tobosutinib. Avoid or adjust dose.r
Theoretical→Also seeTABLE 9p. 849
▶Mitotaneis predicted to very markedly decrease the exposure
tobosutinib. Avoid.rStudy→Also seeTABLE 15p. 850
▶Modafinilis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Netupitantis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical
▶Nevirapineis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Nilotinibis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15
p. 850→Also seeTABLE 9p. 849
▶Bosutinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Pitolisantis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Proton pump inhibitorsare predicted to decrease the
absorption ofbosutinib.oStudy
▶Rifampicinis predicted to very markedly decrease the
exposure tobosutinib. Avoid.rStudy
▶St John’sWortis predicted to decrease the exposure to
bosutinib. Avoid.rTheoretical
Botulinum toxin type A→seeTABLE 20p. 851 (neuromuscular
blocking effects)
Botulinum toxin type B→seeTABLE 20p. 851 (neuromuscular
blocking effects)
Bowel cleansing preparations
SEPARATION OF ADMINISTRATIONOther oral drugs should not be
taken 1 hour before, or after, administration of bowel
cleansing preparations because absorption may be impaired.
Consider withholding ACE inhibitors, angiotensin-II receptor
antagonists, and NSAIDs on the day that bowel cleansing
preparations are given and for up to 72 hours after the
procedure. Also consider withholding diuretics on the day
that bowel cleansing preparations are given.
Brentuximab vedotin→see monoclonal antibodies
Brimonidine→seeTABLE 6p. 848 (bradycardia),TABLE 8p. 848
(hypotension),TABLE 11p. 849 (CNS depressant effects)
Brinzolamide
ROUTE-SPECIFIC INFORMATIONSince systemic absorption can
follow topical application, the possibility of interactions
should be borne in mind.
Brivaracetam→see antiepileptics
Brodalumab→see monoclonal antibodies
Bromfenac→see NSAIDs
Bromocriptine→see dopamine receptor agonistsBNFC 2018 – 2019 Bosentan—Bromocriptine 887
Interactions|Appendix 1A1